Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. TGTX
stocks logo

TGTX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
182.38M
+68.58%
0.254
+69.66%
197.69M
+63.58%
0.340
+1033.33%
215.80M
+52.89%
0.408
+140.19%
Estimates Revision
The market is revising Upward the revenue expectations for TG Therapeutics, Inc. (TGTX) for FY2025, with the revenue forecasts being adjusted by 3.1% over the past three months. During the same period, the stock price has changed by -2.58%.
Revenue Estimates for FY2025
Revise Upward
up Image
+3.1%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+283.88%
In Past 3 Month
Stock Price
Go Down
down Image
-2.58%
In Past 3 Month
Wall Street analysts forecast TGTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TGTX is 45.00 USD with a low forecast of 11.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast TGTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TGTX is 45.00 USD with a low forecast of 11.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
1 Sell
Moderate Buy
Current: 31.380
sliders
Low
11.00
Averages
45.00
High
60.00
Current: 31.380
sliders
Low
11.00
Averages
45.00
High
60.00
JPMorgan
Eric Joseph
Overweight
maintain
$46 -> $49
2025-11-03
Reason
JPMorgan
Eric Joseph
Price Target
$46 -> $49
2025-11-03
maintain
Overweight
Reason
JPMorgan analyst Eric Joseph raised the firm's price target on TG Therapeutics to $49 from $46 and keeps an Overweight rating on the shares. The firm updated the company's model post earnings.
B. Riley
B. Riley
maintain
$53 -> $55
2025-09-17
Reason
B. Riley
B. Riley
Price Target
$53 -> $55
2025-09-17
maintain
Reason
B. Riley raised the firm's price target on TG Therapeutics to $55 from $53 and keeps a Buy rating on the shares. The firm believes the company is positioned for multi-year Briumvi U.S. sales growth. It sees the drug being on track to exceed $1B in the next few years. Riley recommends using the post-earnings selloff in shares of TG as a buying opportunity.
Goldman Sachs
Corinne Johnson
Neutral
initiated
$37
2025-07-10
Reason
Goldman Sachs
Corinne Johnson
Price Target
$37
2025-07-10
initiated
Neutral
Reason
Goldman Sachs analyst Corinne Johnson initiated coverage of TG Therapeutics with a Neutral rating and $37 price target. The firm believes Briuvmi revenue growth will continue to be the key driver of the shares.
HC Wainwright & Co.
Edward White
Strong Buy
Reiterates
$55
2025-03-04
Reason
HC Wainwright & Co.
Edward White
Price Target
$55
2025-03-04
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Edward White
Strong Buy
Reiterates
$55
2025-01-15
Reason
HC Wainwright & Co.
Edward White
Price Target
$55
2025-01-15
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for TG Therapeutics Inc (TGTX.O) is 21.67, compared to its 5-year average forward P/E of 21.17. For a more detailed relative valuation and DCF analysis to assess TG Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
21.17
Current PE
21.67
Overvalued PE
88.39
Undervalued PE
-46.05

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-10.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
76.89
Undervalued EV/EBITDA
-96.88

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
97.13
Current PS
0.00
Overvalued PS
299.52
Undervalued PS
-105.25
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

TGTX News & Events

Events Timeline

(ET)
2025-11-03
07:08:52
TG Therapeutics increases FY25 revenue forecast to $600M, up from $585M, surpassing consensus of $588.12M.
select
2025-11-03
07:07:50
TG Therapeutics announces Q3 earnings per share of $2.43, surpassing consensus estimate of 22 cents.
select
2025-10-28 (ET)
2025-10-28
07:37:44
TG Therapeutics finishes enrolling participants in Phase 3 ENHANCE trial
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
1.0
11-28Newsfilter
TG Therapeutics CEO to Participate in 8th Annual Evercore Healthcare Conference
  • Conference Participation: TG Therapeutics CEO Michael S. Weiss will participate in the 8th Annual Evercore Healthcare Conference on December 2, 2025, showcasing the company's latest advancements in B-cell disease treatments, which is expected to attract investor attention and enhance market confidence.
  • Live Webcast: The fireside chat will be available via live webcast on the company's website, increasing transparency and providing potential investors with direct insights into the company's strategic direction.
  • Product Approval: TG Therapeutics has received FDA approval for BRIUMVI® for the treatment of relapsing forms of multiple sclerosis, marking a significant milestone in the company's commercialization efforts and is expected to drive future revenue growth.
  • Market Positioning: With a focus on innovative treatments for B-cell diseases, TG Therapeutics is poised to capture a significant share of the rapidly growing biopharmaceutical market as BRIUMVI is promoted, thereby enhancing its competitive edge in the industry.
[object Object]
Preview
9.5
11-28NASDAQ.COM
TG Therapeutics TGTX Q3 2025 Earnings Call Transcript
  • Author's Perspective: The views and opinions presented are solely those of the author.
  • No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
[object Object]
Preview
3.5
11-19Newsfilter
TG Therapeutics Named Among America's Fastest-Growing Companies in 2025 Deloitte Technology Fast 500™ List

  • TG Therapeutics Recognition: TG Therapeutics ranked 27th on the Deloitte Technology Fast 500™ for 2025, highlighting its rapid growth driven by BRIUMVI® revenues, which was FDA-approved for treating relapsing forms of multiple sclerosis in December 2022.

  • CEO Statement: Michael S. Weiss, CEO of TG Therapeutics, expressed pride in the company's recognition, attributing it to employee efforts, BRIUMVI® adoption, and the trust of patients and healthcare providers, while reaffirming their commitment to innovation in autoimmune disease treatment.

  • BRIUMVI® Overview: BRIUMVI® (ublituximab-xiiy) is a monoclonal antibody targeting CD20-expressing B-cells, approved for adult patients with relapsing multiple sclerosis, and is designed to efficiently deplete B-cells at low doses.

  • Safety Information: The press release includes important safety information regarding BRIUMVI®, including potential infusion reactions, risks of infections, and contraindications, emphasizing the need for monitoring and precautions during treatment.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is TG Therapeutics Inc (TGTX) stock price today?

The current price of TGTX is 31.38 USD — it has decreased -0.73 % in the last trading day.

arrow icon

What is TG Therapeutics Inc (TGTX)'s business?

TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.

arrow icon

What is the price predicton of TGTX Stock?

Wall Street analysts forecast TGTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TGTX is 45.00 USD with a low forecast of 11.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is TG Therapeutics Inc (TGTX)'s revenue for the last quarter?

TG Therapeutics Inc revenue for the last quarter amounts to 161.71M USD, increased 92.79 % YoY.

arrow icon

What is TG Therapeutics Inc (TGTX)'s earnings per share (EPS) for the last quarter?

TG Therapeutics Inc. EPS for the last quarter amounts to 2.43 USD, increased 12050.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for TG Therapeutics Inc (TGTX)'s fundamentals?

The market is revising Upward the revenue expectations for TG Therapeutics, Inc. (TGTX) for FY2025, with the revenue forecasts being adjusted by 3.1% over the past three months. During the same period, the stock price has changed by -2.58%.
arrow icon

How many employees does TG Therapeutics Inc (TGTX). have?

TG Therapeutics Inc (TGTX) has 338 emplpoyees as of December 05 2025.

arrow icon

What is TG Therapeutics Inc (TGTX) market cap?

Today TGTX has the market capitalization of 4.98B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free